title: Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer.
abstract: Cytolytic activation of peripheral blood lymphocytes by recombinant interleukin-2 (rIL-2) in patients with squamous cell carcinoma (SCC) of the head and neck may be inhibited by serum blocking factors, and this could influence therapeutic efficacy. Peripheral blood lymphocytes from 21 patients with this disease and 17 controls were incubated with 10-1000 U rIL-2 for 6 days in supplemented complete medium (containing 10% fetal calf serum) or the same medium plus 10% autologous serum. After washing the effector cells, we determined their cytotoxicity against K562 and MDA1386, a lymphokine-activated-killer(LAK)-sensitive SCC cell line, using a 51Cr-release assay. Patient sera inhibited LAK-generated lysis of both MDA1386 and K562, while control sera from healthy persons inhibited LAK-generated lysis of MDA1386. The blocking activity of patient sera tended to be greater than that of control sera. The sera of patients with untreated or recurrent disease and those who were free of disease had equivalent inhibitory capacity. The serum blocking factor acted in a dose-dependent manner, and inhibition was overcome by increasing the dose of rIL-2. Levels of circulating immune complexes (measured by the C1q binding method) did not correlate significantly with inhibition. A clinical protocol of repeated plasma exchange in patients with advanced and recurrent squamous cell carcinoma of the head and neck allowed sequential study of one patients's serum before, during, and after treatments. Plasmapheresis removed serum inhibitory factors, albeit temporarily. The activity of serum blocking factors in patients with this disease can be modulated by increasing doses of rIL-2 and by plasma exchange. This modulation may be important to improving clinical response rates for patients undergoing immunotherapy.
authors.affiliation: Department of Surgery, Queen's University, Kingston, Ontario.
authors.forename: S P
authors.initials: SP
authors.lastname: Bugis
authors.forename: E
authors.initials: E
authors.lastname: Lotzová
authors.forename: H E
authors.initials: HE
authors.lastname: Savage
authors.forename: J P
authors.initials: JP
authors.lastname: Hester
authors.forename: T
authors.initials: T
authors.lastname: Racz
authors.forename: P G
authors.initials: PG
authors.lastname: Sacks
authors.forename: S P
authors.initials: SP
authors.lastname: Schantz
mesh_terms: D000936:Antigen-Antibody Complex / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D006258:Head and Neck Neoplasms / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D007376:Interleukin-2 / Q000008:administration & dosage; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D010951:Plasma Exchange; D011994:Recombinant Proteins; D013491:Suppressor Factors, Immunologic / Q000097:blood
chemical_list: D000936:Antigen-Antibody Complex; D007376:Interleukin-2; D011994:Recombinant Proteins; D013491:Suppressor Factors, Immunologic